ELIC.ST实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 23:29):

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden...

Stats
今日成交量	422 202
平均成交量	99 109.00
市值	18.79M
EPS	SEK-0.255 ( 2023-11-14 )
下一个收益日期	( SEK0 ) 2024-05-16
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.140
ATR14	SEK0.00600 (0.63%)

音量相关性

長: 0.02 (neutral)

短: 0.44 (neutral)

Signal:(44.604) Neutral

Elicera Therapeutics AB 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Elicera Therapeutics AB 相关性 - 货币/商品

0.17
( neutral )

0.00
( neutral )

0.11
( neutral )

-0.17
( neutral )

-0.15
( neutral )

Elicera Therapeutics AB 财务报表

Annual	2023
营收:	SEK0
毛利润:	SEK-11 776.00 (0.00 %)
EPS:	SEK-0.830

FY	2023
营收:	SEK0
毛利润:	SEK-11 776.00 (0.00 %)
EPS:	SEK-0.830

FY	2022
营收:	SEK1.28M
毛利润:	SEK1.27M (99.08 %)
EPS:	SEK-0.990

FY	2021
营收:	SEK587.00
毛利润:	SEK0.00 (0.00 %)
EPS:	SEK-0.663

Financial Reports:

No articles found.

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.